PMID- 21561398
OWN - NLM
STAT- MEDLINE
DCOM- 20111101
LR  - 20220317
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 27
IP  - 7
DP  - 2011 Jul
TI  - Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal 
      patches in mild to moderate Alzheimer's disease: a multicenter, randomized, 
      open-label, parallel-group study.
PG  - 1375-83
LID - 10.1185/03007995.2011.582484 [doi]
AB  - OBJECTIVE: To compare the tolerability and efficacy of combination therapy of 
      memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients 
      with mild to moderate Alzheimer's disease (AD). RESEARCH DESIGN AND METHODS: In 
      this multicenter, randomized, open-label study, patients entered an 8-week run-in 
      period (a 5 cm 2 rivastigmine patch for 4 weeks, then a 10 cm(2) patch for 4 
      weeks) followed by 16 weeks of memantine plus rivastigmine patch or rivastigmine 
      patch monotherapy. The primary outcome measure was the retention rate at the end 
      of the trial. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov. NCT01025466. 
      RESULTS: Overall, 88 and 84 patients received rivastigmine patch with and without 
      memantine, respectively, and of these, 77 (87.5%) and 70 (83.3%) patients 
      completed the study. The difference in retention rate was not significant (95% 
      confidence interval: -6.3-14.7%). The incidence of adverse events (AEs) (53.4 vs. 
      50.6%) and discontinuation due to AEs (6.8 vs. 4.8%) were not different between 
      patients with and without memantine. The most frequent AEs were skin irritation 
      in patients with and without memantine (42.0 vs. 34.9%, p = 0.71), but 
      discontinuation due to skin irritation was rare (4.5 vs. 2.4%, p = 0.74). The 
      incidence of gastrointestinal AEs was very low in patients with and without 
      memantine (nausea, 2.3 vs. 1.2%; vomiting, 1.1 vs. 1.2%). The Korean Version of 
      the Cohen Mansfield Agitation Inventory scores favored rivastigmine patch 
      monotherapy at the end of treatment (p = 0.01). Changes in other efficacy 
      measures were similar between the groups. CONCLUSION: There were no significant 
      differences in tolerability and safety between the treatment groups. The 
      combination therapy of memantine plus rivastigmine patch did not show an 
      advantage over rivastigmine patch monotherapy on efficacy analyses. The sample 
      size for comparing tolerability may have been too small to detect a difference of 
      efficacy between the two groups.
FAU - Choi, Seong Hye
AU  - Choi SH
AD  - Department of Neurology, Inha University School of Medicine, Incheon, South 
      Korea.
FAU - Park, Kyung Won
AU  - Park KW
FAU - Na, Duk L
AU  - Na DL
FAU - Han, Hyun Jeong
AU  - Han HJ
FAU - Kim, Eun-Joo
AU  - Kim EJ
FAU - Shim, Yong S
AU  - Shim YS
FAU - Lee, Jae-Hong
AU  - Lee JH
CN  - Expect Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01025466
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20110512
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Phenylcarbamates)
RN  - PKI06M3IW0 (Rivastigmine)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Administration, Cutaneous
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy
MH  - Antiparkinson Agents/administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Memantine/*administration & dosage/*adverse effects
MH  - Middle Aged
MH  - Neuroprotective Agents/administration & dosage/adverse effects
MH  - Phenylcarbamates/*administration & dosage/adverse effects
MH  - Rivastigmine
MH  - Severity of Illness Index
MH  - Transdermal Patch
MH  - Treatment Outcome
FIR - Kim, Byeong-Chae
IR  - Kim BC
FIR - Na, Hae Ri
IR  - Na HR
FIR - Lee, Jun-Young
IR  - Lee JY
FIR - Moon, So Young
IR  - Moon SY
FIR - Kwon, Jay C
IR  - Kwon JC
FIR - Ryu, Seung-Ho
IR  - Ryu SH
FIR - Kim, Jung Eun
IR  - Kim JE
FIR - Ku, Bon D
IR  - Ku BD
FIR - Kim, Shin Gyeom
IR  - Kim SG
FIR - Park, Kee Hyung
IR  - Park KH
FIR - Park, Key-Chung
IR  - Park KC
FIR - Yoon, Soo Jin
IR  - Yoon SJ
FIR - Park, Jong-Moo
IR  - Park JM
FIR - Heo, Jae-Hyeok
IR  - Heo JH
FIR - Choi, Mun Seong
IR  - Choi MS
FIR - Yi, Hyon-Ah
IR  - Yi HA
FIR - Park, Hyun Young
IR  - Park HY
FIR - Shin, Joon-Hyun
IR  - Shin JH
FIR - Cho, Soo Jin
IR  - Cho SJ
EDAT- 2011/05/13 06:00
MHDA- 2011/11/02 06:00
CRDT- 2011/05/13 06:00
PHST- 2011/05/13 06:00 [entrez]
PHST- 2011/05/13 06:00 [pubmed]
PHST- 2011/11/02 06:00 [medline]
AID - 10.1185/03007995.2011.582484 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2011 Jul;27(7):1375-83. doi: 10.1185/03007995.2011.582484. 
      Epub 2011 May 12.